How do you pay?

How to pay the least

Ask for the cash price

Tavneos

We didn’t find one.

  1. Ask your pharmacy for Tavneos’s cash price, and one or two other pharmacies too.
  2. Tavneos’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Amgen Safety Net Foundation. Amgen Safety Net Foundation income requirements are based on a percentage of the Federal Poverty Level, adjusted for household size. Or call 1-800-932-3060.

See if you qualify 

Compare every option

Question
Brand nameTavneos
Authorized genericavacopan
Regular genericavacopan
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Tavneos?
The original
–
–

Brand nameThe maker’s card

TAVNEOS Copay Program

Savings card from Amgen (ChemoCentryx)

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a month

Sign up on tavneos.com 

Or call 1-833-828-6367.

In the maker’s words

“Eligible commercially insured patients may pay as little as $0 for a month’s supply of TAVNEOS® with the TAVNEOS® Copay Program…”

From the maker’s offer on tavneos.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Tavneos itself, from the same company, sold without the brand name, and usually for less. For now Tavneos is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

TAVNEOS is a complement 5a receptor (C5aR) antagonist indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use.

Source: the FDA label for Tavneos (ChemoCentryx, Inc.), June 2, 2026. Full label on DailyMed 

Good to know